Pharmacogenetics and pharmacogenomics

Queneau, 2003, Effets indésirables médicamenteux observés dans des Services d’Accueil et d’Urgences français (Etude prospective de l’APNET et propositions pour des mesures préventives), Bull. Acad. Natle Med., 187, 647 Kohn, 2000 Beutler, 1993, Study of glucose-6-phoshate deshydrogenase : history and molecular biology, Am. J. Hematol., 42, 53, 10.1002/ajh.2830420111 Shi, 2001, Enabling large-scale pharmacogenetic studies by high throughput mutation detection and genotyping technologies, Clin. Chem., 47, 164, 10.1093/clinchem/47.2.164 Allorge, 2004, La pharmacogénétique ou la promesse d’une médecine personnalisée : variations du métabolisme et du transport des médicaments, Ann. Biol. Clin., 62, 499 Ilkinson, 2005, Drug metabolism and variability among patients in drug response, New Engl. J. Med., 352, 2211, 10.1056/NEJMra032424 Ingelman-Sundberg, 2005, Genetic polymorphisms of cytochrome P4502D6 (CYP2D6) : clinical consequences, evolutionary aspects and functional diversity, The Pharmacogenomics J., 5, 6, 10.1038/sj.tpj.6500285 Gasche, 2004, Codeine intoxication associated with ultrarapid CYP2D6 metabolism, New Engl. J. Med., 351, 2867, 10.1056/NEJMoa041888 Kirchheiner, 2004, Pharmacogenetics of antidepressants and antipsychotics : the contribution of allelic variations to the phenotype of drug response, Mol. Psychiatry, 9, 442, 10.1038/sj.mp.4001494 Dervieux, 1999, Thiopurine methyltransferase activity and its relationship to the occurence of rejection episodes in pediatric renal transplant recipients with azathioprine, Br. J. Clin. Pharmacol., 48, 780, 10.1046/j.1365-2125.1999.00087.x Ando, 2000, Polymorphisms of UDP-glucuronyltransferase gene and irinotecan toxicity : a pharmacogenetic analysis, Cancer Res., 60, 6921 Hoffmeyer, 2000, Functional polymorphisms of the human multidrug resistance gene : multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo, Proc. Natl. Acad. Sci. (USA), 97, 3473, 10.1073/pnas.97.7.3473 Vacheron, 2004, Recommandations concernant les traitements anticoagulants par les antivitamines K, Bull. Acad. Natle Med., 188, 867 Gage, 2004, The genetics of vitamin K antagonists, The Pharmacogenomics J., 4, 224, 10.1038/sj.tpj.6500258 Bodin, 2005, Cytochrome P4502C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity, Blood, 106, 135, 10.1182/blood-2005-01-0341 Wei, 1996, Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity, J. Clin. Invest., 98, 610, 10.1172/JCI118830 Ulrich, 2001, Pharmacogenetics of methotrexate : toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism, Blood, 98, 231, 10.1182/blood.V98.1.231 Hetherington, 2002, Genetic variations in HLA-B region and hypersensitivity to abacavir, Lancet, 359, 1121, 10.1016/S0140-6736(02)08158-8 Stearns, 2004, Pharmacogenetics in the treatment of breast cancer, The Pharmacogenomics J., 4, 143, 10.1038/sj.tpj.6500242 Khalili, 2005, Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer, Oncogene, 24, 6657, 10.1038/sj.onc.1208790 Hostein, 2004, Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material : a potential tool for the diagnosis of atypical lipomatous tumours/well-differentiated liposarcomas, J. Pathol., 202, 95, 10.1002/path.1495 Khalili, 2005, Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer Mukohara, 2005, Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations, Natl Cancer Inst., 97, 1185, 10.1093/jnci/dji238 Bourel M., Ardaillou R. — Les centres de ressources biologiques dans les établissements de soins. Bull, 2002, Acad. Natle Med., 186, 1551 http://www.genemedrx.com Smits, 2005, A review on the design and reporting of studies on drug-gene interactions, J. Clin. Epidemiol., 58, 651, 10.1016/j.jclinepi.2005.01.001 Food and Drug Administration. Pharmacogenomic data submissions. En ligne dans http://www.drugresearcher.com Commission consultative nationale en matière d’examen des caractéristiques génétiques à des fins médicales. Rapport d’activité 200-2003. Ministère de la solidarité, de la santé et de la famille.